Evaluation of Intratumoral Response Heterogeneity in Metastatic Colorectal Cancer and Its Impact on Patient Overall Survival: Findings from 10,551 Patients in the ARCAD Database

Imagem de Miniatura
Arquivos
art_OU_Evaluation_of_Intratumoral_Response_Heterogeneity_in_Metastatic_Colorectal_2023.PDF (5.25 MB)
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
MDPI
Autores
OU, Fang-Shu
AHN, Daniel H.
DIXON, Jesse G.
GROTHEY, Axel
LOU, Yiyue
KASI, Pashtoon M.
HUBBARD, Joleen M.
CUTSEM, Eric Van
SALTZ, Leonard B.
SCHMOLL, Hans-Joachim
Citação
CANCERS, v.15, n.16, article ID 4117, 17p, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Metastatic colorectal cancer (mCRC) is a heterogeneous disease that can evoke discordant responses to therapy among different lesions in individual patients. The Response Evaluation Criteria in Solid Tumors (RECIST) criteria do not take into consideration response heterogeneity. We explored and developed lesion-based measurement response criteria to evaluate their prognostic effect on overall survival (OS). Patients and Methods: Patients enrolled in 17 first-line clinical trials, who had mCRC with & GE; 2 lesions at baseline, and a restaging scan by 12 weeks were included. For each patient, lesions were categorized as a progressing lesion (PL: > 20% increase in the longest diameter (LD)), responding lesion (RL: > 30% decrease in LD), or stable lesion (SL: neither PL nor RL) based on the 12-week scan. Lesion-based response criteria were defined for each patient as follows: PL only, SL only, RL only, and varied responses (mixture of RL, SL, and PL). Lesion-based response criteria and OS were correlated using stratified multivariable Cox models. The concordance between OS and classifications was measured using the C statistic. Results: Among 10,551 patients with mCRC from 17 first-line studies, varied responses were noted in 51.6% of patients, among whom, 3.3% had RL/PL at 12 weeks. Among patients with RL/SL, 52% had stable disease (SD) by RECIST 1.1, and they had a longer OS (median OS (mOS) = 19.9 months) than those with SL only (mOS = 16.8 months, HR (95% CI) = 0.81 (0.76, 0.85), p < 0.001), although a shorter OS than those with RL only (mOS = 25.8 months, HR (95% CI) = 1.42 (1.32, 1.53), p < 0.001). Among patients with SL/PL, 74% had SD by RECIST 1.1, and they had a longer OS (mOS = 9.0 months) than those with PL only (mOS = 8.0 months, HR (95% CI) = 0.75 (0.57, 0.98), p = 0.040), yet a shorter OS than those with SL only (mOS = 16.8 months, HR (95% CI) = 1.98 (1.80, 2.18), p < 0.001). These associations were consistent across treatment regimen subgroups. The lesion-based response criteria showed slightly higher concordance than RECIST 1.1, although it was not statistically significant. Conclusion: Varied responses at first restaging are common among patients receiving first-line therapy for mCRC. Our lesion-based measurement criteria allowed for better mortality discrimination, which could potentially be informative for treatment decision-making and influence patient outcomes.
Palavras-chave
tumor measurement-based endpoints, cancer trials
URI
https://observatorio.fm.usp.br/handle/OPI/57378
Referências
  1. Al-Shamsi HO, 2016, J GASTROINTEST ONCOL, V7, P499, DOI 10.21037/jgo.2016.06.16
  2. Baldeo C, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.8_suppl.122
  3. Bennouna J, 2013, LANCET ONCOL, V14, P29, DOI 10.1016/S1470-2045(12)70477-1
  4. Chatwal MS, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.e21037
  5. Choi H, 2007, J CLIN ONCOL, V25, P1753, DOI 10.1200/JCO.2006.07.3049
  6. COCHRAN WG, 1952, ANN MATH STAT, V23, P315, DOI 10.1214/aoms/1177729380
  7. COX DR, 1972, J R STAT SOC B, V34, P187
  8. Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025
  9. Davnall F, 2012, INSIGHTS IMAGING, V3, P573, DOI 10.1007/s13244-012-0196-6
  10. de Gramont A, 2010, J CLIN ONCOL, V28, P527, DOI 10.1200/JCO.2009.25.2544
  11. Douillard JY, 2013, NEW ENGL J MED, V369, P1023, DOI 10.1056/NEJMoa1305275
  12. Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026
  13. European Medicines Agency, 2023, EV ANT MED PROD MAN
  14. Farhangfar CJ, 2013, CLIN CHEM, V59, P38, DOI 10.1373/clinchem.2012.194712
  15. FDA, 2018, CLIN TRIAL ENDP APPR
  16. FLEUREN GJ, 1995, IMMUNOL REV, V145, P91, DOI 10.1111/j.1600-065X.1995.tb00078.x
  17. Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4
  18. Jonker DJ, 2007, NEW ENGL J MED, V357, P2040, DOI 10.1056/NEJMoa071834
  19. Kalbfleisch J.D., 1980, STAT ANAL FAILURE TI, pxi
  20. KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868
  21. Kogita A, 2015, BIOCHEM BIOPH RES CO, V458, P52, DOI 10.1016/j.bbrc.2015.01.064
  22. Kopetz S, 2019, NEW ENGL J MED, V381, P1632, DOI 10.1056/NEJMoa1908075
  23. KRUSKAL WH, 1952, J AM STAT ASSOC, V47, P583, DOI 10.1080/01621459.1952.10483441
  24. Lips EH, 2008, CLIN CANCER RES, V14, P772, DOI 10.1158/1078-0432.CCR-07-2052
  25. Llovet JM, 2008, JNCI-J NATL CANCER I, V100, P698, DOI 10.1093/jnci/djn134
  26. Marusyk A, 2010, BBA-REV CANCER, V1805, P105, DOI 10.1016/j.bbcan.2009.11.002
  27. MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6
  28. Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156
  29. Natale, 2018, J CANC CLIN, V1, P1005
  30. Nishino M, 2013, CLIN CANCER RES, V19, P3936, DOI 10.1158/1078-0432.CCR-13-0895
  31. Phipps AI, 2015, GASTROENTEROLOGY, V148, P77, DOI 10.1053/j.gastro.2014.09.038
  32. Seymour L, 2017, LANCET ONCOL, V18, pE143, DOI 10.1016/S1470-2045(17)30074-8
  33. Shiu KK, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.2020.38.18_suppl.LBA4
  34. Sobrero AF, 2008, J CLIN ONCOL, V26, P2311, DOI 10.1200/JCO.2007.13.1193
  35. Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205
  36. van Emburgh BO, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13665
  37. van Kessel CS, 2013, EUR J CANCER, V49, P2486, DOI 10.1016/j.ejca.2013.03.027
  38. Yonesaka K, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002442

Coleções
Artigos e Materiais de Revistas Científicas - FM/MDR
Artigos e Materiais de Revistas Científicas - LIM/24
Artigos e Materiais de Revistas Científicas - ODS/03